Available on demand: Measuring the cost of the right interventions in diabetes

Louise-Bellamy-pharmaphorum-200

Our one-hour live webinar that delved into measuring the cost of the right interventions in diabetes took place on Thursday 8th September.

Diabetes is one of the most prevalent and costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of the disease, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective in terms of both cost and patient impact is an equally complicated process.

This webinar explored the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.

Topics covered included:

  • The burden of diabetes – prevalence and cost of the disease and its complications
  • The challenges of early diagnosis and prevention
  • The challenges of diabetes modelling and future opportunities
  • How modelling will aid the value and access argument
  • Learnings from global markets
  • Recent case studies – successes and failures

The live webinar took place on Thursday 8 September at 15.00 BST / 16.00 CEST. To view this webinar on demand, please click here or on the button above/below.

Height_700px

Participants


John Grumitt.jpgJohn Grumitt
(Vice President, International Diabetes Federation and Diabetes UK)

John is Vice President of the International Diabetes Federation. Locally he is also Vice President of Diabetes UK. He was a trustee of the charity from 2003-2012 and Vice Chair from 2006-2012. John is a regular contributor to policy reviews, holding a number of posts at NHSE as well as advising a range of stakeholder organisations.

John has type 1 diabetes and otherwise leads a full and active lifestyle, completing numerous endurance cycling events including the Stykreproven 545 km non stop across Norway.

Having built a number of consumer centred businesses here and across Europe, he turned his attention to high quality patient centred healthcare and is managing director of award winning advisors, Metapath (www.metapathsolutions.com), enabling policy makers, commissioners and providers to achieve better outcomes with less resource. John also chaired Platform Health, whose global health data interoperability standard, H.860 was approved by the United Nations’ ITU in 2014.

Last month he led a spin out from Newcastle University’s medical faculty called Changing Health which will provide on line patient and HCP education backed up by ongoing behaviour change coaching. All of this will be evidenced based.

He is a chartered accountant and attended the Wharton Business School.

Phil McEwanDr Phil McEwan (IMS Health Associate and Diabetes HE modelling ‎advisor)

Phil has 28 years of experience in costing, quality of life, and modeling studies across a spectrum of disease areas, both in academia and health economics consulting.

As a co-founder of Cardiff Research Consortium (CRC), Phil has spent six years as Technical Director, developing stochastic simulation models and undertaking multivariate statistical analysis of routine healthcare data for use in health technology submissions. He is a Director at the Centre for Health Economics, Swansea University and Managing Director of Health Economics and Outcomes Research Ltd.

He has provided support for diabetes disease modeling and statistical analysis of healthcare data, also investigating the use and validity of cardiovascular risk functions in type 2 diabetes.

Prof Michael TrenellProfessor Michael Trenell (Professor of Metabolism & Lifestyle Medicine, Newcastle University)

Mike is a Professor of Metabolism & Lifestyle Medicine and National Institute for Health Research Senior Fellow at Newcastle University, UK. He is interested in how lifestyle affects the body, from glucose control and cardiorespiratory fitness to liver fat and brain perfusion. In Newcastle he is Director of MoveLab and leads a multidisciplinary team of clinical academic researchers in one of the UK’s leading Clinical Lifestyle Laboratories. Aside from lifestyle and metabolism, Mike has a strong interest in digital health and behaviour change, developing and implementing scalable programmes for people with type 2 diabetes.

 

Paul-Tunnah-BW-200x200

Paul Tunnah (CEO, pharmaphorum media)

Dr Paul Tunnah founded pharmaphorum media in 2009 which has rapidly evolved and developed its offerings to drive better communication, connection and collaboration between the pharmaceutical industry and other stakeholders. Today the groups spans expertise in publishing and consulting around content-driven customer engagement. The offerings are underpinned by the common strengths of extensive global networks, a firm finger on the pulse of changing market dynamics, and deep expertise in creating engaging, relative media. Prior to this, Dr Tunnah obtained a BA in Biochemistry and DPhil in Biological Sciences from Oxford University, before working in commercial consulting for Datamonitor, IMS Health and SmartAnalyst.

Dr Tunnah can be contacted by emailing paul@pharmaphorum.com or tweeting @pharmaphorum.